Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Catalyst Pharmaceuticals stock

Learn how to easily invest in Catalyst Pharmaceuticals stock.

Catalyst Pharmaceuticals Inc is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Pharmaceuticals employs 76 staff and has a trailing 12-month revenue of around $170.5 million.

How to buy shares in Catalyst Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CPRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Catalyst Pharmaceuticals stock price (NASDAQ: CPRX)

Use our graph to track the performance of CPRX stocks over time.

Catalyst Pharmaceuticals shares at a glance

Information last updated 2022-09-27.
Latest market close$12.70
52-week range$5.04 - $17.22
50-day moving average $12.60
200-day moving average $8.55
Wall St. target price$16.90
PE ratio 24.18
Dividend yield $0 (0%)
Earnings per share (TTM) $0.50

Buy Catalyst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catalyst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catalyst Pharmaceuticals price performance over time

Historical closes compared with the close of $12.7 from 2022-09-29

1 week (2022-09-23) 6.99%
1 month (2022-09-01) -9.16%
3 months (2022-07-01) 79.89%
6 months (2022-04-01) 52.46%
1 year (2021-10-01) 143.76%
2 years (2020-10-01) 305.75%
3 years (2019-10-01) 154.00%
5 years (2017-09-29) 403.97%

Is Catalyst Pharmaceuticals stock undervalued or overvalued?

Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Catalyst Pharmaceuticals's P/E ratio

Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Catalyst Pharmaceuticals shares trade at around 24x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Catalyst Pharmaceuticals's EBITDA

Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72.8 million.

The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Catalyst Pharmaceuticals financials

Revenue TTM $170.5 million
Operating margin TTM 42.64%
Gross profit TTM $102 million
Return on assets TTM 19.07%
Return on equity TTM 25.35%
Profit margin 31.97%
Book value $2.35
Market capitalisation $1.2 billion

TTM: trailing 12 months

Catalyst Pharmaceuticals share dividends

We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.

Catalyst Pharmaceuticals share price volatility

Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $5.04 up to $17.22. A popular way to gauge a stock's volatility is its "beta".

CPRX.US volatility(beta: 1.31)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.3116. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Catalyst Pharmaceuticals overview

Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc.

Frequently asked questions

What percentage of Catalyst Pharmaceuticals is owned by insiders or institutions?
Currently 6.295% of Catalyst Pharmaceuticals shares are held by insiders and 76.308% by institutions.
How many people work for Catalyst Pharmaceuticals?
Latest data suggests 76 work at Catalyst Pharmaceuticals.
When does the fiscal year end for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals's fiscal year ends in December.
Where is Catalyst Pharmaceuticals based?
Catalyst Pharmaceuticals's address is: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
What is Catalyst Pharmaceuticals's ISIN number?
Catalyst Pharmaceuticals's international securities identification number is: US14888U1016
What is Catalyst Pharmaceuticals's CUSIP number?
Catalyst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 14888U101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site